CancerNetwork Members: Login | Register
Become a fan on  Facebook  Add us on  Google Plus Follow us on  Twitter Join us on LinkedIn Sign up for our Newsletters Subscribe to our RSS Feed

 

CancerNetwork SearchMedica Medline Drugs

Powered by SearchMedica

 
PUBLICATIONS
NEWS
PODCASTS
TOPICS
BLOGS
NURSES
PATIENTS
JOBS
CONFERENCES
CME
SUPPLEMENTS
 

Home »

ONCOLOGY. Vol. 20 No. 5
Pages: 1  2  
Next
The Plante/Roy Article Reviewed 

Fertility-Preserving Options for Cervical Cancer

By

LINDA R. DUSKA, MD
Assistant in Gynecology
and Obstetrics
Massachusetts General
Hospital Cancer Center
Boston, Massachusetts

| April 17, 2006

When the radical trachelectomy procedure was first presented by Dargent at the 1994 meeting of the Society of Gynecologic Oncologists,[1] it was considered innovative and experimental. Medical professionals worried that conservative surgery would be less successful than radical hysterectomy in controlling cancer. By 2006, data reported largely by Dargent and Plante and summarized in the current article have suggested that, for appropriately selected patients, the risk of cancer recurrence associated with fertility-preserving surgery is similar to that of the traditional surgical approach.

Complex Questions

When, then, does it become the "standard of care" to offer the option of this conservative procedure to women of reproductive age who are diagnosed with cervical cancer of limited extent? What volume of reported cases is required before gynecologic oncologists accept radical trachelectomy as a standard therapeutic option for appropriately selected patients with stage IB cervical cancer?

These questions are complex and multifactorial. The cancer control question is apparently not a major concern, assuming that patients are chosen carefully using criteria that have become increasingly refined. The optimal selection criteria, however, remain elusive. What methods should be employed to choose good candidates for this procedure? What potential complications need to be considered?

As the authors of the current review note, infertility and preterm delivery are two significant problems encountered after radical trachelectomy. How are these difficulties best addressed? Are there other options that we should be discussing with our patients?

Patient Selection

Data presented by the authors demonstrate that young women with lesions smaller than 2 cm who have no lymphovascular invasion are appropriate candidates for radical trachelectomy. It is essential to exclude disease beyond the cervix, and if we accept radical trachelectomy as a standard option, we are obliged to define a standard clinical and imaging evaluation designed to identify appropriate candidates.

Magnetic resonance imaging, a diagnostic tool mentioned by the authors, is probably the best currently available modality to identify parametrial spread and extension into the upper endocervix and myometrium—two findings that would render radical trachelectomy inappropriate. In addition, positron-emission tomography/computed tomography can be helpful in identifying spread to retroperitoneal lymph nodes, particularly in squamous lesions, and should be considered preoperatively for patients contemplating radical trachelectomy.[2]

As concerns about cancer recurrence subside, infertility and obstetric complications emerge as significant problems. Infertility rates after an abdominal approach seem similar to those found after a vaginal approach, but the data are limited.[3] In our own experience, infertility secondary to cervical factors has been a problem (unpublished data). Obstetric complications, particularly preterm delivery, should be addressed preoperatively.

Pages: 1  2  
Next
 

Join the Conversation

Want to join the conversation? If you're a healthcare professional, we'd like to hear your comments. Just sign in or register today to become part of our growing, online community.

This commentary refers to the following article

Fertility-Preserving Options for Cervical Cancer






 
TOPIC INDEX

Cancer Types

 
  • Breast
  • Breast (HER2+)
  • Breast (Triple-Negative)
  • CML
  • Colorectal
  • Gastrointestinal
  • GIST
  • Genitourinary
  • Gynecologic
  • Head & Neck
  • Hematology
  • Kidney (Renal Cell)
  • Leukemia
  • Lung
  • Lymphoma
  • Melanoma
  • Multiple Myeloma
  • Ovarian
  • Prostate
  • Sarcoma

Supportive Care

More Topics

  • Bone Metastases
  • End-of-Life Care
  • Palliative Care
  • Ethics in Oncology
  • Practice Management
  • Practice & Policy


All Topics 


 
IMAGE IQ

Lower Back Pain in an Elderly Man With a History of Localized Prostate Cancer
James B. Yu, MD1 , May 17, 2013

A 70-year-old man with a history of localized prostate cancer treated with whole-pelvis radiation therapy with a boost to the prostate, in conjunction with androgen deprivation therapy 7 years prior, presented with lower back pain. A bone scan revealed an area of activity in the sacrum. What is the most likely diagnosis?

More Image IQs 

 
FROM PHYSICIANS PRACTICE
Primary Care Can't Thrive Without Nurse Practitioners
Courtney H. Lyder, ND,  May 17, 2013
With a projected shortfall of primary-care physicians, it's time for alternate solutions to patient care. Nurse practitioners are one logical remedy.
VWhat Physicians Can Learn from the Allscripts EHR Lawsuit
Marisa Torrieri,  May 16, 2013
Lawsuit prompts question: What should physicians do to ensure they end up with a great EHR instead of buyer’s remorse?
Eight Ways ICD-9 Will Still Matter to Medical Practices
Brenda Edwards, CPC,  May 15, 2013
What should your medical practice do with your ICD-9-CM book after October 1, 2014? Keep it.
Seven Ways Technology Can Speed Up Patient Collections
Cheyenne Brinson,  May 15, 2013
Failing to adopt widely available billing and collections technology can cost medical practices big. Here's how to do it right.
Four Reasons Private Medical Practice is Becoming Extinct
Carol Stryker,  May 15, 2013
It’s becoming increasingly difficult for private medical practices to thrive. Here’s what’s driving the trend toward consolidation.
 

 

 
MOST POPULAR
  • Most Popular
  • Most Emailed
  • Most Recent
  • Colorectal Lesions
  • Dermatologic Adverse Events Associated With Targeted Therapies
  • “This Is My Last Day on Earth”
  • Slide Show: Squamous Cell Carcinoma of the Head and Neck
  • Skin Lesions
  • “This Is My Last Day on Earth”
  • Recurrent Epithelial Ovarian Cancer: An Update on Treatment
  • Dermatologic Adverse Events Associated With Targeted Therapies
  • ONS: Understanding Spirituality and How It Can Be Used to Help Patients
  • Colorectal Lesions
  • New AUA Guidelines for Prostate Cancer Screening
  • 50 Shades of Pink—And Why It Helps to Know the Difference
  • Genomics Studies Identify Testicular Cancer Risk Variants
  • Lower Back Pain in an Elderly Man With a History of Localized Prostate Cancer
  • FDA Approves Erlotinib (Tarceva) as First-Line Lung Cancer Therapy for Certain Patients
Click here to subscribe to our newsletter
 
COMMENTS
  • Most Commented
  • Most Recent
  • “This Is My Last Day on Earth”
  • Financial Toxicity, Part II: How Can We Help With the Burden of Treatment-Related Costs?
  • Patient Quality of Life Endpoints in Oncology Trials, Part II
  • Who's Coding Whom?
  • “How Do I Say This Nicely? Your Oncologist Wasn't Following Guidelines”
  • Preventing Exposure to Hazardous Drugs
  • Cancer Metabolism as a Therapeutic Target
  • Study: Cholesterol Drugs Reduced Risk of Prostate Cancer Death
  • “This Is My Last Day on Earth”
  • ONS: Safe Handling of Chemotherapy
Click here to subscribe to our newsletter



CancerNetwork on Facebook

CancerNetwork | ConsultantLive | Diagnostic Imaging | Musculoskeletal Network | OBGYN.net | PediatricsConsultantLive |
Physicians Practice | Psychiatric Times | SearchMedica | Medical Resources

© 1996 - 2013 UBM Medica LLC, a UBM company
Privacy Statement - Terms of Service - Advertising Information - Editorial Policy Statement - UBM Medica Network Privacy Policy